277 related articles for article (PubMed ID: 16469744)
1. Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice.
Xu J; Gong NL; Bodi I; Aronow BJ; Backx PH; Molkentin JD
J Biol Chem; 2006 Apr; 281(14):9152-62. PubMed ID: 16469744
[TBL] [Abstract][Full Text] [Related]
2. MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure.
van Oort RJ; van Rooij E; Bourajjaj M; Schimmel J; Jansen MA; van der Nagel R; Doevendans PA; Schneider MD; van Echteld CJ; De Windt LJ
Circulation; 2006 Jul; 114(4):298-308. PubMed ID: 16847152
[TBL] [Abstract][Full Text] [Related]
3. Translation of Myocyte Enhancer Factor-2 is induced by hypertrophic stimuli in cardiomyocytes through a Calcineurin-dependent pathway.
Ye J; Cardona M; Llovera M; Comella JX; Sanchis D
J Mol Cell Cardiol; 2012 Oct; 53(4):578-87. PubMed ID: 22850285
[TBL] [Abstract][Full Text] [Related]
4. Bone morphogenetic protein-2 acts upstream of myocyte-specific enhancer factor 2a to control embryonic cardiac contractility.
Wang YX; Qian LX; Liu D; Yao LL; Jiang Q; Yu Z; Gui YH; Zhong TP; Song HY
Cardiovasc Res; 2007 May; 74(2):290-303. PubMed ID: 17367767
[TBL] [Abstract][Full Text] [Related]
5. Myocyte enhancer factor 2A is transcriptionally autoregulated.
Ramachandran B; Yu G; Li S; Zhu B; Gulick T
J Biol Chem; 2008 Apr; 283(16):10318-29. PubMed ID: 18073218
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation and alternative pre-mRNA splicing converge to regulate myocyte enhancer factor 2C activity.
Zhu B; Gulick T
Mol Cell Biol; 2004 Sep; 24(18):8264-75. PubMed ID: 15340086
[TBL] [Abstract][Full Text] [Related]
7. New polymorphisms in human MEF2C gene as potential modifier of hypertrophic cardiomyopathy.
Alonso-Montes C; Naves-Diaz M; Fernandez-Martin JL; Rodriguez-Reguero J; Moris C; Coto E; Cannata-Andia JB; Rodriguez I
Mol Biol Rep; 2012 Sep; 39(9):8777-85. PubMed ID: 22718505
[TBL] [Abstract][Full Text] [Related]
8. Cross-talk between glycogen synthase kinase 3β (GSK3β) and p38MAPK regulates myocyte enhancer factor 2 (MEF2) activity in skeletal and cardiac muscle.
Dionyssiou MG; Nowacki NB; Hashemi S; Zhao J; Kerr A; Tsushima RG; McDermott JC
J Mol Cell Cardiol; 2013 Jan; 54():35-44. PubMed ID: 23137781
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor induces MEF2C and MEF2-dependent activity in endothelial cells.
Maiti D; Xu Z; Duh EJ
Invest Ophthalmol Vis Sci; 2008 Aug; 49(8):3640-8. PubMed ID: 18450586
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy.
Konno T; Chen D; Wang L; Wakimoto H; Teekakirikul P; Nayor M; Kawana M; Eminaga S; Gorham JM; Pandya K; Smithies O; Naya FJ; Olson EN; Seidman JG; Seidman CE
Proc Natl Acad Sci U S A; 2010 Oct; 107(42):18097-102. PubMed ID: 20923879
[TBL] [Abstract][Full Text] [Related]
11. The calcineurin-myocyte enhancer factor 2c pathway mediates cardiac hypertrophy induced by endoplasmic reticulum stress in neonatal rat cardiomyocytes.
Zhang ZY; Liu XH; Hu WC; Rong F; Wu XD
Am J Physiol Heart Circ Physiol; 2010 May; 298(5):H1499-509. PubMed ID: 20207814
[TBL] [Abstract][Full Text] [Related]
12. Regulation of MEF2 transcriptional activity by calcineurin/mAKAP complexes.
Li J; Vargas MA; Kapiloff MS; Dodge-Kafka KL
Exp Cell Res; 2013 Feb; 319(4):447-54. PubMed ID: 23261540
[TBL] [Abstract][Full Text] [Related]
13. The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice.
Kim Y; Phan D; van Rooij E; Wang DZ; McAnally J; Qi X; Richardson JA; Hill JA; Bassel-Duby R; Olson EN
J Clin Invest; 2008 Jan; 118(1):124-32. PubMed ID: 18079970
[TBL] [Abstract][Full Text] [Related]
14. mef2c is activated directly by myogenic basic helix-loop-helix proteins during skeletal muscle development in vivo.
Dodou E; Xu SM; Black BL
Mech Dev; 2003 Sep; 120(9):1021-32. PubMed ID: 14550531
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the human GLUT4 gene promoter: interaction between a transcriptional activator and myocyte enhancer factor 2A.
Knight JB; Eyster CA; Griesel BA; Olson AL
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):14725-30. PubMed ID: 14630949
[TBL] [Abstract][Full Text] [Related]
16. Disruption of MEF2 activity in cardiomyoblasts inhibits cardiomyogenesis.
Karamboulas C; Dakubo GD; Liu J; De Repentigny Y; Yutzey K; Wallace VA; Kothary R; Skerjanc IS
J Cell Sci; 2006 Oct; 119(Pt 20):4315-21. PubMed ID: 17003108
[TBL] [Abstract][Full Text] [Related]
17. Differences in MEF2 and NFAT transcriptional pathways according to human heart failure aetiology.
Cortés R; Rivera M; Roselló-Lletí E; Martínez-Dolz L; Almenar L; Azorín I; Lago F; González-Juanatey JR; Portolés M
PLoS One; 2012; 7(2):e30915. PubMed ID: 22363514
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II induces myocyte enhancer factor 2- and calcineurin/nuclear factor of activated T cell-dependent transcriptional activation in vascular myocytes.
Suzuki E; Nishimatsu H; Satonaka H; Walsh K; Goto A; Omata M; Fujita T; Nagai R; Hirata Y
Circ Res; 2002 May; 90(9):1004-11. PubMed ID: 12016267
[TBL] [Abstract][Full Text] [Related]
19. The MEF2 transcriptional target DMPK induces loss of sarcomere structure and cardiomyopathy.
Damanafshan A; Elzenaar I; Samson-Couterie B; van der Made I; Bourajjaj M; van den Hoogenhof MM; van Veen HA; Picavet DI; Beqqali A; Ehler E; De Windt LJ; Pinto YM; van Oort RJ
Cardiovasc Res; 2018 Sep; 114(11):1474-1486. PubMed ID: 29648621
[TBL] [Abstract][Full Text] [Related]
20. Modulation of angiotensin II-mediated cardiac remodeling by the MEF2A target gene Xirp2.
McCalmon SA; Desjardins DM; Ahmad S; Davidoff KS; Snyder CM; Sato K; Ohashi K; Kielbasa OM; Mathew M; Ewen EP; Walsh K; Gavras H; Naya FJ
Circ Res; 2010 Mar; 106(5):952-60. PubMed ID: 20093629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
